ABT-737 and/or folate reverse the PDGF-induced alterations in the mitochondrial apoptotic pathway in low-grade glioma patients by Debien, Emilie et al.
ORIGINAL ARTICLE
ABT-737 and/or folate reverse the PDGF-induced alterations
in the mitochondrial apoptotic pathway in low-grade
glioma patients
Emilie Debien & Eric Hervouet & Fabien Gautier &
Philippe Juin & Francois M. Vallette &
Pierre-Francois Cartron
Received: 24 February 2011 /Accepted: 10 April 2011 /Published online: 15 May 2011
# The Author(s) 2011. This article is published with open access at Springerlink.com
Abstract Elevated activation of the platelet-derived growth
factor (PDGF) pathway, apoptosis evasion phenotype, and
global DNA hypomethylation are hallmarks frequently
observed in cancers, such as in low-grade glioma (LGG).
However, the orchestration of these malignant functions is
not fully elucidated in LGG. Our study reveals that the co-
presence of these hallmarks in the same LGG is frequent
and confers poor prognosis in patients with LGG. Our data
also indicate that the apoptosis evasion phenotype of these
cells harboring a hypomethylation-induced activation of the
PDGF pathway is associated with a hypomethylation of the
bcl-xl and bcl-w genes and the phosphorylation and/or
downregulation of three major pro-apoptotic BH3-only
proteins: PUMA, Bad, and Bim. Consistent with this, we
demonstrate that the use of folate, a DNA-methylating agent,
promotes the reprogramming of the sensitivity of glioma
cells to ABT-737/etoposide-induced apoptosis and reduces
the dose of ABT-737 required to promote etoposide-induced
apoptosis. This work supports the idea that the inclusion of
folate and/or ABT-737 could be a promising adjuvant in the
design of anti-glioma therapeutic protocols in clinical studies.
Abbreviations
Dnmt DNA methyltransferase
LGG Low-grade glioma
5mC 5-Methylcytosine
Introduction
Acquired resistance to apoptosis or programmed cell death
is one of the hallmarks of human cancer (Hanahan and
Weinberg 2000). Defects in the apoptotic pathway and the
disruption of the apoptotic program contribute to tumor
initiation and progression, as well as to treatment resistance,
since most current anti-cancer treatments including chemo-
therapy, radio- and immunotherapy act primarily by
promoting cell death via the induction of apoptosis (Lowe
and Lin 2000; Evan and Vousden 2001).
Studies over the last decade that aimed at identifying the
underlying molecular mechanisms of apoptosis resistance
have delineated multiple defects at various levels of the
apoptosis signal transduction machinery. Among these
multiple defects reported are changes in the expression of
members of the Bcl-2 protein family that is a major cause
for the resistance to apoptosis in tumor cells (Reed 2003).
Thus, the presence of an “apoptosis evasion phenotype” in
tumor cells is largely associated with the overexpression of
certain anti-apoptotic proteins such as Bcl-2, Bcl-xl, and
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low expression level, mutations, proteosomal degradation,
and/or sequestration of certain pro-apoptotic proteins such
as Bax, Bim, Bad, HRK, Bik, or Noxa (Martin et al. 2001).
In glioma, these points have been illustrated and demon-
strated by the fact that (1) high levels of Bcl-2 and/or Bcl-xl
confer a resistance to radio- and/or chemotherapeutic drugs
and promote the intracranial growth of glioma (Weller et al.
1995; Nagane et al. 1998; Del Bufalo et al. 2001; Bougras
et al. 2004; Weiler et al. 2006), (2) Bax deficiency confers a
high resistance to apoptosis induction (Cartron et al. 2003),
(3) HRK is inactivated in astrocytic tumors, and this
reduced HRK expression contributes to the loss of
apoptotic control in high-grade tumors (Nakamura et al.
2005). Thus, the elucidation of these pathways over the past
two decades has raised the possibility of developing and
using therapies targeting the Bcl-2 protein family in order
to induce apoptosis in tumor cells.
Among the multiple therapeutic strategies targeting the
Bcl-2 protein family is the antagonism of the pro-survival
function of anti-apoptotic proteins that seems to be the most
attractive strategy. We and others have reported that HA14-1,
the first small-molecule Bcl-2 inhibitor, has the capacity to
overcome chemo- and radioresistance caused by Bcl-2 over-
expression (Wang et al. 2000;M a n e r oe ta l .2006;O l i v e re t
al. 2007). Several additional small-molecule inhibitors of
anti-apoptotic proteins have been described including thea-
flavins and epigallechatechins, terphenyl derivates,
NSC365400 (compound 6), gossypol derivates, GX015-
070, and ABT-737 (Enyedy et al. 2001;K u t z k ie ta l .2002;
Leone et al. 2003; Pellecchia and Reed 2004; Oltersdorf et
al. 2005; Reed and Pellecchia 2005; Lessene et al. 2008).
The latter molecule is the most potent and specific Bcl-2/
Bcl-xl/Bcl-w inhibitor discovered to date. Mechanistic
studies have revealed that ABT-737 is associated with the
dissociation of interactions between pro-apoptotic and anti-
apoptotic Bcl-2 family members, the change in conformation
of Bax, cytochrome c release from mitochondria, and the
activation of caspases (Oltersdorf et al. 2005;K o j i m ae ta l .
2006; Konopleva et al. 2006; van Delft et al. 2006).
Recently, we published that it is possible to abolish the
“apopto-resistance” phenotype of glioma cells by reducing
the expression of anti-apoptotic proteins such as Bcl-w via
the folate-induced DNA (hyper)methylation of genes
encoding these proteins (Hervouet et al. 2009). Based on
these observations, we here complemented this point by (1)
dissecting the mechanisms by which a folate treatment
abrogates the “apopto-resistance” phenotype of glioma
cells, (2) demonstrating that folate and ABT-737 can work
together to reprogram the sensitivity of certain gliomas to
the etoposide-induced apoptosis, (3) showing that the use of
folate minimizes the dose of ABT-737 necessary to promote
etoposide-induced apoptosis.
Results
Activation of the PDGF pathway correlates with a low
degree of global DNA methylation and the presence
of an apoptosis evasion phenotype in low-grade glioma
Low-grade glioma (LGG) tumors have an elevated
platelet-derived growth factor (PDGF) signaling path-
way, an “apoptosis evasion phenotype,” and a global
DNA hypomethylation pattern. We initially searched for
potential correlations between these three parameters in
a collection of 65 LGG. For this purpose, we assessed
the DNA methylation status by quantifying the number
of the 5-methylcytosine (5mC) present on DNA by
using an ELISA method. The phenotype of apoptosis
evasion was estimated via the measure of intratumor
apoptotic level through the activation of caspase-3/7
(referred as DEVDase activity) since caspase/DEVDase
activity is the end step in apoptosis. The measurement of
PDGF receptor beta (PDGFrβ) kinase activity was
performed to assess the degree of activation of the PDGF
pathway. All these parameters were plotted against each
other, and a statistical analysis using Pearson’s correlation
test indicated the presence of significant correlations
between these parameters (Fig. 1a). This study showed
that 31% (20/65; group A) of the LGG was characterized
by the simultaneous presence of a high PDGFrβ activity
(higher or equal to the median value), a low level of DNA
methylation (lower than the median value), and a low
DEVDase activity (lower than the median value), while
28% (18/65; group B) of the LGG was characterized by
the opposite hallmarks (Fig. 1b).
We continued our study with these two groups. Firstly,
we noted that the presence of these hallmarks was not
associated with the histology of the LGG because a similar
number of astrocytoma, oligodendrocytoma, or oligoastro-
cytoma were included in these two subgroups (Fig. 1b).
Secondly, by estimating and comparing the survival curves
for these two subgroups using Kaplan–Meier curve and the
Cox proportional hazards survival regression analysis, we
observed a statistical difference in the survival of these two
groups of patients indicating that co-presence in LGG of a
high PDGFrβ activity, a low level of DNA methylation,
and a low DEVDase activity as a poor prognostic factor
(Fig. 1c).
Collectively, these results suggest that the PDGF
pathway plays an important role in apoptosis evasion in
LGG, that this hallmark could be epigenetically regulated,
and that the co-presence of a high PDGFrβ activity, a low
level of DNA methylation, and a low DEVDase activity in
LGG could be used as an alternative predictor of disease
outcome and/or biomarker to select a subpopulation of
patients.
370 Clin Epigenet (2011) 2:369–381The apoptosis evasion phenotype of Ntv-a/PDGF cells
is generated by the disruption of the apoptotic program
at the mitochondrial step symbolized by the loss
of Bax activation.
To develop a therapeutic protocol based on a molecular
rationale and able to promote apoptosis in tumor cells
characterized by a low DNA methylation, a low intratumor
apoptosis, and an elevated PDGF signaling pathway, we
chose to use the Ntv-a/PDGF cells as these cells harbor
these three signatures, as previously reported (Dai et al.
2001; Hervouet et al. 2009). In addition to using Ntv-a/
LacZ cells as a control (non-tumor cells generated via a
RCAS-LacZ infection), PDGFr activity was inhibited using
a PDGFr tyrosine kinase inhibitor III or PDGFr inhibitor
(PDGFri; Calbiochem #521232) or by promoting its
silencing via the folate-induced methylation of the PDGFrβ
gene (Fig. S1). Folate was also used to abolish the presence
of DNA hypomethylation mechanisms of “apopto-resis-
tance” in Ntv-a/PDGF cells.
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Fig. 1 PDGF pathway activation correlates with the low degree of
global DNA methylation and the presence of the apoptosis evasion
phenotype in low-grade glioma (LGG). a Correlation between the
degree of global DNA methylation (i.e., the number of 5-
methylcytosine, 5mC) and the degree of apoptosis (i.e., the DEVDase
activity), the degree of PDGFrβ activity and the degree of apoptosis
(i.e., the DEVDase activity), and between the degree of PDGFrβ
activity and the degree of global DNA methylation (i.e., the number of
5-methylcytosine, 5mC) in 65 LGG. 5mC was estimated by using the
Methylamp Global DNA Methylation Quantification kit (Epigentek-
Euromedex, France). PDGFrβ activity was assessed by using the
HTScan® PDGF Receptor β Kinase Assay Kit (Ozyme, France).
DEVDase activity was measured as previously described (Cartron et
al. 2002). b Representation of the patient number whose LGG is
characterized by the presence of a high PDGFrβ activity (higher or
equal to the median value), a low level of DNA methylation (lower to
the median value), and a low DEVDase activity (lower to the median
value). AII grade II astrocytoma, OAII grade II oligoastrocytoma, OII
grade II oligodendrocytoma. c Kalpan–Meier estimates of survival
time for patients whose tumors had a high PDGFrβ activity (higher or
equal to the median value), a low level of DNA methylation (lower to
the median value), and a low DEVDase activity (lower to the median
value) (in black) and those whose tumors did not (in gray)
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confirmed that the PDGFri or the folate treatment of Ntv-a/
PDGF cells increased the UV-induced apopto-sensitivity of
these cells and limited the hypomethylation status of these
cells compared to the Ntv-a/LacZ cells (Fig. 2a; Hervouet et
al. 2009). In other terms, our data underlined the presence,
in Ntv-a/PDGF cells, of molecular mechanisms inhibiting
the apoptosis induced by UV and showed that these
mechanisms were methylation-dependent and/or PDGF-
dependent since folate (a DNA-methylating agent) or
PDGFri treatments resensitized these Ntv-a/PDGF cells to
apoptosis.
We then decided to identify the PDGF dependence and/or
the methylation dependence of these molecular mechanisms
conferring the phenotype of apoptosis evasion in LGG cells.
For this purpose, we first investigated whether the apoptosis
evasion of Ntv-a/PDGF cells was due to a negative regulation
of the mitochondrial step in the apoptotic program by
assessing the quantity of cytochrome c released from
mitochondria after UV induction of apoptosis. The choice of
UV to induce apoptosis is due to the fact that UV induces
apoptosis by multiple processes including DNA damage,
activation of the tumor suppressor gene p53, triggering of cell
deathreceptorseitherdirectlybyUVorbyautocrinereleaseof
death ligands, mitochondrial damage, and cytochrome c
release (Kulms and Schwarz 2000). Subcellular fractionation
and densitometric analysis of Western blots revealed that the
quantity of cytochrome c released from mitochondria in Ntv-
a/PDGF cells was greatly inferior to that released from
mitochondria in Ntv-a/PDGF cells treated with folate or
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Fig. 2 The apoptosis phenotype
evasion is associated with the
loss of Bax activation. a Effect
of the folate or PDGFri (PDGFri
0.5 μM Calbiochem, France)
treatment on the level of DNA
methylation (i.e., on the 5meth-
ylcytosine number, 5mC) and on
the UV-induced apoptosis. b
Effect of the folate or PDGFri
treatment on the cytochrome c
release in cytosol (C) from mi-
tochondria (M) via subcellular
fractionation experiment. F1-
ATPase is used as control of
mitochondrial protein. c Effect
of the folate or PDGFri treat-
ment on the cytochrome c re-
lease in cytosol (C) from
mitochondria (M) via confocal
microscopy experiment. F1-
ATPase is used as control of
mitochondrial protein. CF rep-
resents the correlation factor or
co-localization of F1-ATPase (i.
e., mitochondria) with cyto-
chrome c. The pictures are rep-
resentative of at least 100
different cells. d Effect of the
folate or PDGFri treatment on
degree of Bax activation via the
Bax6A7-immunoprecipitation
(IP) method. Western blot (WB)
is performed to analyze the
effect of the folate or PDGFr
i
treatment on the Bax expression.
Actin is used as loading control.
All experiments were done after
7 days of treatment as previous-
ly described (Hervouet et al.
2009)
372 Clin Epigenet (2011) 2:369–381PDGFri (Fig. 2b). Confocal microscopy and MetaMorph
analyses confirmed this result (Fig. 2c).
Since the latter results indicated that Ntv-a/PDGF cells
harbored a disruption of the apoptotic program at the
mitochondrial step, we analyzed the level of activated Bax
after UV treatment because the activation of Bax is a
crucial event in mitochondrial step of apoptotic program
leading to the release of apoptogenic proteins (such as the
cytochrome c) from the mitochondria. We performed
Bax6A7 immunoprecipitation since Bax activation is
characterized by the exposure of the amino terminal epitope
recognized by the monoclonal antibody 6A7 (Hsu and
Youle 1997). After UV-induced apoptosis, the quantity of
activated Bax (or Bax6A7 positive) was lower in Ntv-a/
PDGF than in Ntv-a/PDGF cells treated with folate or
PDGFri, while the levels of total Bax remained unchanged
in these cells (Fig. 2d). Thus, these results demonstrate that
the disruption of the apoptotic program at the mitochondrial
step present in Ntv-a/PDGF cells was due to the absence of
Bax activation.
The low level of Bax activation in Ntv-a/PDGF cells
is associated with the low level of PUMA and Bim induced
by PDGF-Akt/FoxO3a signaling and the presence of pBim
via the activation of PDGF/Erk signaling.
We next attempted to identify the molecular causes
inducing the loss of Bax activation in Ntv-a/PDGF cells.
For this purpose, we determined whether the loss of Bax
activation in Ntv-a/PDGF cells was associated with low
expression pro-apoptotic BH3-only proteins. We focused
our study on the level of expression of five pro-apoptotic
BH3-only proteins: Bid, Bad, Bim, PUMA, and Noxa. Our
experiments reveal no association between the level of Bax
activation and the expression levels of Bad, Bid, and Noxa.
However, we noted a concordance between the expression
level of Bim (notably BimEL isoform) or PUMA and the
level of Bax activation (Figs. 2d and 3a). This suggests that
the loss of Bax activation in Ntv-a/PDGF cells was, in part,
due to the low level of expression of PUMA and Bim, both
BH3-only proteins that have the capacity to activate Bax.
Toidentifythe mechanism(s)leading tothe low expression
level of PUMA and Bim in Ntv-a/PDGF cells, we firstly
quantified that the mRNAs coding for PUMA and Bim were
overexpressed in Ntv-a/PDGF cells treated with PDGFri or
folate (Fig. 3b). Since both PUMA and Bim are partially
under the transcriptional control of FoxO3a, we analyzed the
transcriptional activity of FoxO3a using the plasmid reporter
method. As illustrated in Fig. 3b,b o t hf o l a t ea n dP D G F r i
increased the FoxO3a transcriptional activity in Ntv-a/PDGF
cells. These data suggest the presence of a FoxO3a inhibition
mechanism in Ntv-a/PDGF cells. We also show that (1) the
low transcriptional activity of FoxO3a in Ntv-a/PDGF cells
was associated with its high phosphorylation in a context of
high PDGF-induced Akt activity and (2) an Akt inhibitor
treatment of Ntv-a/PDGF cells restored the high transcrip-
tional activity of FoxO3a and a high expression of mRNAs
coding for PUMA and Bim. Taken together, these results
demonstrate that the low level of Bax activation in Ntv-a/
PDGF cells is, in part, due to the low expression level of
Bim and PUMA as a result of a negative regulation of
FoxO3a initiated by PDGF and mediated by Akt.
Concerning Bim, we complemented our study by
observing that the Ntv-a/PDGF cells harbored a high level
of phospho-Bim (pBim), while the PDGFri and folate
treatments decreased the presence of pBim in Ntv-a/PDGF
cells (Fig. 3c). In addition, we noted that pBim was due to
the PDGF–Erk pathway because the pBim level decreased
when Ntv-a/PDGF cells were treated with PDGFri or
U0126 (an Erk1/2 inhibitor). Thus, these observations
reinforced and corroborated the relationship underlined
above and existing between the low expression level of
Bim and the low apoptosis level seen in Ntv-a/PDGF cells
because literature reports that the Bim phosphorylation
abrogates the pro-apoptotic function of this BH3-only
protein via its degradation or via its incapacity to activate
Bax (Harada et al. 2003; Luciano et al. 2003).
Overexpression of Bcl-w and Bcl-xl in Ntv-a/PDGF cells
participates in the low level of Bax activation.
We next analyzed whether the loss of Bax activation in
Ntv-a/PDGF cells was also associated with the over-
expression of anti-apoptotic proteins since these proteins
block cell death signaling by antagonizing Bax activation.
Western blot analyses of the expression levels of Mcl-1,
Bcl-2, Bcl-w, and Bcl-xl proteins in Ntv-a/PDGF cells
treated or not with PDGFri or folate revealed that these
cells overexpressed Bcl-w and Bcl-xl (Fig. 4a). This
observation was also validated at the transcriptome level
(Fig. 4b).
We then asked whether the high expression of Bcl-w
mRNA
and Bcl-xl
mRNA was dependent on the nuclear factor κB
(NFκB) activity in Ntv-a/PDGF cells as NFκB has been
shown to regulate the expression of these transcripts (Tran et
al. 2005). The data presented in Fig. 4c using a NFκB
inhibitor confirmed this observation. We also showed that
the high transcriptional activity of NFκBi nN t v - a / P D G F
was associated with the presence of high levels of phospho-
IκBα and a high Akt activity, while the low transcriptional
activity of NFκB was associated with the presence of low
levels of phospho-IκBα and a low Akt activity in Ntv-a/
PDGF cells treated with folate or PDGFri (Fig. 4d).
Based on the DNA-methylating function of folate, we
hypothesized that the downregulation of both Bcl-w
mRNA
and Bcl-xl
mRNA observed in Ntv-a/PDGF cells treated with
Clin Epigenet (2011) 2:369–381 373folate could be due to the methylation of the promoters of
both bcl-x and bcl-w. Consistent with the fact that NFκB
regulates the transcription of both bcl-x and bcl-w genes, we
designed primers to assess the methylation status of the
NFκB boxes localized within the promoter regions of these
two genes. MSP revealed that the CG dinucleotides included
within the NFκB boxes of both the bcl-x and bcl-w genes
were unmethylated in Ntv-a/PDGF cells, but methylated
when these cells were treated with folate (Fig. 4e).
Thus, our data indicate that the high expression of Bcl-xl
and Bcl-w seen in Ntv-a/PDGF cells is due to the PDGF-
initiated Akt/IκBα-mediated activation of NFκBi na
context of unmethylation of the DNA-binding domains of
this transcription factor localized within the promoter
regions of the bcl-x and bcl-w genes.
Functional hierarchy of the Bcl-2 family members
in Ntv-a/PDGF cells
We next studied the relationship between the level of Bax
activation andtheinteractions existing betweentheBcl-2, Bcl-
xl, and Bcl-w proteins and Bax, PUMA, and Bim proteins.
Changes in the expression of the anti-apoptotic proteins
in these cells were quantified by immunoprecipitations
performed on CHAPS cell extracts from Ntv-a/PDGF cells
treated or not with folate or PDGFri. Under these
conditions, the comparison of co-immunoprecipitated pro-
teins from Ntv-a/PDGF cells treated or not with folate or
PDGFri revealed that the Ntv-a/PDGF cells were charac-
terized by the strong inhibition of Bax by Bcl-2, Bcl-xl, and
Bcl-w, a high antagonism of PUMA and Bim by Bcl-2,
Bcl-xl, and Bcl-w, and a low neutralization of Bcl-2, Bcl-xl,
and Bcl-w by Bad (Fig. 5a). Thus, this result associates the
apopto-resistance of Ntv-a/PDGF cells with the loss of Bax
activation as a result of its inhibition by Bcl-2, Bcl-xl, and
Bcl-w (Fig. 5a). Immunoprecipitation experiments also
revealed a strong antagonism of PUMA and Bim by Bcl-
2, Bcl-xl, and Bcl-w in Ntv-a/PDGF cells, and that this
antagonism was reduced by PDGFri or folate treatments of
Ntv-a/PDGF cells. All these results indicate that (1) the
apoptosis evasion phenotype harbored by the Ntv-a/PDGF
cells is, in part, due to the antagonism of pro-apoptotic
proteins by the anti-apoptotic proteins and (2) the folate-
induced apopto-sensitivity of Ntv-a/PDGF cells is associ-
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Fig. 3 The apoptosis phenotype
evasion is associated with the
loss of Bax activation. a Effect
of the folate or PDGFri treat-
ment on the expression levels of
BH3-only proteins. Actin is
used as loading control. b Rela-
tive Bim
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expressions were estimated by
qPCR. Transcriptional FoxO3a
activity was estimated by using
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the expression levels of FoxO3a
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374 Clin Epigenet (2011) 2:369–381ated with the dissociation of pro-apoptotic and anti-
apoptotic protein interactions.
Taken into consideration the roles of activators and/or
sensitizers/derepressors of BH3-only proteins and on their
hierarchical regulation, our data seem to indicate that the
weak neutralization of Bcl-2, Bcl-xl, and Bcl-w by Bad
could be at the origin of the strong antagonism of Bax,
PUMA, and Bim by these same anti-apoptotic proteins.
Based on the above data, we investigated whether Bad
has the capacity to displace PUMA or Bim from anti-
apoptotic proteins. For this purpose, we developed an
acellular assay in which the capacity of a given BH3
domain to disrupt the co-immunoprecipitation of a given
anti-apoptotic protein with a considered BH3-only protein
was analyzed. Consistent with a previous report (Kim et al.
2006), we noted that Bad
BH3 displaced PUMA and Bim
from anti-apoptotic proteins such as Bcl-xl, while
PUMA
BH3 or Bim
BH3 was unable to displace Bad, Bim,
or PUMA from Bcl-xl (Fig. 5b ). In addition to the fact that
Bad has the capacity to displace Bax from anti-apoptotic
proteins, these results strongly suggest that the strong
inhibition or antagonism of Bax, Bim, and PUMA by
Bcl-2, Bcl-xl, and Bcl-w is, in part, due to the weak
neutralization of these anti-apoptotic proteins by Bad.
We next extended our study to the identification of
factors promoting the weak neutralization of Bcl-2, Bcl-xl,
and Bcl-w by Bad observed in Ntv-a/PDGF cells. For this
purpose, we asked whether the process was associated with
the presence of Akt-induced phospho-Bad (pBad
S136)
because this posttranslational modification is known to
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Clin Epigenet (2011) 2:369–381 375abrogate the capacity of Bad to bind the anti-apoptotic
proteins and Akt is activated by the PDGF signaling
pathway. Our analyses revealed that it was the case because
the high levels of pBad
S136 and Akt activity were
associated with the weak neutralization of the anti-
apoptotic proteins by Bad in Ntv-a/PDGF cells, while the
inverse situation was observed when these cells were
treated with PDGFri, Akt, and strikingly with folate
(Fig. 5c).
Thus, these results identify the loss of Bad pro-apoptotic
function as a molecular determinant governing the apopto-
sis evasion phenotype of Ntv-a/PDGF cells and suggest that
the restoration of Bad pro-apoptotic function could abrogate
the apoptosis evasion phenotype of Ntv-a/PDGF cells. To
summarize, all our results support the idea that the
apoptosis evasion phenotype of Ntv-a/PDGF cells is
favored by the loss of pro-apoptotic function of Bad,
PUMA, and Bim in a context of overexpression of anti-
apoptotic proteins.
Effect of the folate and/or ABT-737 pretreatment
on etoposide-induced cell death of PCTC-LGG
Our previous experiments demonstrate that a folate treat-
ment abrogates the PDGF-induced apoptosis evasion
phenotype of Ntv-a/PDGF cells by methylating certain
genes (bcl-w and bcl-xl), and by reorchestrating the
hierarchical interactions of the Bcl-2 family members, we
next compared the effect of folate and/or ABT-737 on
etoposide-induced apopto-sensibility of primary cultured
tumor cells obtained from human LGG (PCTC-LGG). We
used this approach because, like folate, ABT-737 (a
chemotherapeutic agent that docks within the hydrophobic
groove of anti-apoptotic proteins, thereby disabling their
capacity to antagonize the actions of pro-apoptotic proteins)
has a weak single-agent cell-killing activity but promotes
apoptosis in combination with anti-cancer agents unable to
initially elicit apoptosis in cancer cells (Oltersdorf et al.
2005; van Delft et al. 2006).
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376 Clin Epigenet (2011) 2:369–381PCTC-LGG used were obtained from tumors character-
ized by the presence of a high PDGFrβ activity, a low level
of 5-methylcytosine, and a low level of intratumor
apoptosis intratumor of a high level, a high level of pBad,
and the unmethylation of the bcl-w and bcl-xl genes, i.e., by
molecular signatures characterizing the Ntv-a/PDGF cells.
Thus, among the 20 LGG exhibiting a high PDGFrβ
activity, a low level of 5-methylcytosine, and a low level of
apoptosis intratumor of a high level, 60% (12/20) presented
a high level of pBad and unmethylation of bcl-w gene
simultaneously, and 2 different tumors of these 12 were
used to obtain PCTC#LGG-1 and -2 (Fig. 6a).
As expected, we initially noted that ABT-737 and folate
have weak single-agent cell-killing activity because these
components induced less than 20% of cell death (Fig. 6b).
Secondly, our data indicated that ABT-737 and folate
promoted massive cell death (equal or superior to 60%) in
PCTC#LGG-1 when used in association with etoposide. In
addition, the synergy of ABT-737 and etoposide is also
supported by the fact that cell death increased when the
ABT-737 concentration increased (p=0.0424). Thirdly, we
noted that the triple combination of folate/ABT-737
(0.1 μM)/etoposide was more effective than the double
combination of folate/etoposide or ABT-737 (0.1 μM)/
etoposide (p=0.0334, p=0.0031). Fourthly, our data indi-
cated that the use of folate in combination with ABT-737
and etoposide permitted a reduction in the concentration of
ABT-737 used to induce massive cell death in PCTC#LGG-
1 because no significant difference was observed between
the percentage of cell death obtained between PCTC#LGG-
1 treated with folate/ABT-737 (0.1 μM)/etoposide and
folate/ABT-737 (10 μM)/etoposide (p=0.6803). Lastly,
similar experiments done with PCTC#LGG-2 indicated
that ABT-737/etoposide was weakly toxic in these cells in
comparison with folate/etoposide (18%, 22%, and 67% cell
death, p=0.0016 and p=0.0017). In other terms, folate
amplified the etoposide-induced cell death in PCTC#LGG-
2 cells but not ABT-737. However, we noted that ABT-737
amplified the folate/etoposide-induced death in
PCTC#LGG-2 cells (p=0.0397, p=0.0376) and this inde-
pendently of the dose of ABT-737 (p=0.8601).
Thus, these results indicate that we can reverse the cell
death resistance in LGG to anti-cancer agents by using
folate and/or ABT-737. In addition, our work indicates that
the use of folate in combination with ABT-737/etoposide
can markedly enhanced the response of LGG cells to ABT-
737/etoposide and may minimize the dose of ABT-737 in
order to reduce the ABT-737-induced co-lateral damage,
even if this drug is generally well tolerated (Oltersdorf et al.
2005; Konopleva et al. 2006).
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Recent advances in the identification of the molecular
mechanisms that govern the chemo-resistance of cancer
cells via the acquisition of apoptosis evasion phenotype
have provided meaningful progress in the treatment of
many human cancers. However, much more has to be done
in order to design successful therapeutic protocols based on
rational molecular targeting and the treatment personaliza-
tion. Recently, we have begun to unveil that folate
treatment has the capacity to increase apopto-sensitivity of
Ntv-a/PDGF cells, i.e., in LGG cells induced by the
constitutive activation of PDGF signaling pathway and
characterized by a low level of DNA methylation and a
phenotype of apopto-resistance (Hervouet et al. 2009).
However, not much is known about how folate abrogates
PDGF-induced resistance of anti-cancer treatments for the
benefit of an apopto-sensitivity to these same anti-cancer
treatments.
We have focused in this study on the role of folate in
PDGF-induced dysfunctions in the apoptotic pathway
responsible for resistance to anti-cancer drugs/treatments
in low-grade glioma cells. Our data support the interest of
this search because we found that the simultaneous
presence of high PDGFr kinase activity, low level of
DNA methylation, and low intratumor apoptosis constitutes
a hallmark correlated with a poor survival prognosis in
patients suffering from LGG. In addition, our results
suggest that the presence of these three hallmarks could
be used as a biomarker of disease outcome in LGG and/or
for rational selection of patients susceptible to a personal-
ized anti-cancer treatment including folate. However, the
incorporation of folate into anti-glioma therapy must be
supported by other experiments since folate as other
epigenetic drugs may have a dual role in cancer prevention
or progression because folate supplementation may de-
crease the risk of common cancers. Besides, numerous
reports support this duality suggesting that high folate
treatment may be associated with an increase in the risk of
colorectal and prostate cancers in a randomized controlled
trial and increase risk of breast cancer, while a low dose of
folate may protect against colorectal cancer (Stolzenberg-
Solomon et al. 2006; Van Guelpen et al. 2006; Cole et al.
2007; Lindzon et al. 2009; Stidley et al. 2010). Thus, since
the importance of the dose schedule of the 5-aza-2′-
deoxycytidine treatment in epigenetic therapy of cancer,
the dose schedule of the folate treatment is certainly
important (Lemaire et al. 2008).
Due to its dual role in PDGF signaling pathway and on
the methylation status of genes coding for Bcl-w and Bcl-xl
anti-apoptotic proteins, our data demonstrate that folate
amplifies etoposide-induced apoptosis by dissociating Bax,
Bim, and PUMA pro-apoptotic proteins from Bcl-2, Bcl-xl,
and Bcl-w anti-apoptotic proteins for the benefit of Bad/
Bcl-2, Bad/Bcl-xl, and Bad/Bcl-w interactions in a context
of low expression of Bcl-xl and Bcl-w and of non-
phosphorylation of Bad. Thus, these results support and
complement the idea of an alternative model of hierarchical
activation of pro-apoptotic functions of BH3-only proteins
(Cartron et al. 2004; Certo et al. 2006; Kim et al. 2006;
Gallenne et al. 2009). In other terms, we can speak of a
model in which Bim and PUMA can activate directly Bax
when they are no longer antagonized by Bcl-2, Bcl-xl, and
Bcl-w anti-apoptotic proteins, i.e., when Bad (or other
BH3-only proteins) engages and represses Bcl-2, Bcl-xl,
and Bcl-w anti-apoptotic proteins. Consequently, the fact
that the folate treatment “activates” the pro-apoptotic
function of Bad via its non-phosphorylation indicates that
this treatment acts, in part, likely by mimicking the effects
of BH3 peptides or BH3 mimetic components. However,
this activity is indirect since it is mediated by Bad, whereas
that of BH3 mimetic components is direct since the majority
of these small molecules have the capacity to bind anti-
apoptotic proteins, leading to the disruption of interactions
existing between anti- and pro-apoptotic proteins such as
BH3-only proteins. Nevertheless, our data argue that folate
and BH3 mimetic components such as ABT-737 have other
common characteristics than the capacity to displace BH3-
only proteins from its binding partners such as Bcl-2, Bcl-xl,
and Bcl-w (Oltersdorf et al. 2005; Zhang et al. 2007b).
Indeed, our data indicate that they have weak single-agent
cell-killing activity, while they enhanced etoposide-induced
cell death. In addition and despite the fact that these
compounds share similar targets, it seems that folate and
ABT-737 can work in synergy to amplify etoposide-induced
cell death because the triple combination of folate/ABT-737/
etoposide is more efficient than the double combination of
folate/etoposide or ABT-737/etoposide. This point is also
supported by the fact that the addition of ABT-737 to
Ntv-a/PDGF cells treated with folate increases the release of
Bim and PUMA from Bcl-xl (Fig. S2).
Due to the fact that interactions between pro- and anti-
apoptotic proteins can be directly or indirectly disrupted by
ABT-737 and folate treatment, it appears that the combina-
tion of folate and ABT-737 markedly amplifies etoposide-
induced cell death and permits a reduction in ABT-737
doses. This point is crucial for the future use of ABT-737 in
preclinical and/or clinical application because there are
reports that ABT-737 can reduce lymphocyte counts and
can cause dose-dependent acute thrombocytopenia by
reducing the number of circulating platelets, whose turn-
over is regulated by apoptosis, even if ABT-737 seems to
be well tolerated in animal model, or by normal hemato-
poietic and bone marrow cells (Oltersdorf et al. 2005;
Konopleva et al. 2006; Mason et al. 2007; Zhang et al.
2007a).
378 Clin Epigenet (2011) 2:369–381Finally, the capacity of folate to promote ABT-737/
etoposide-induced cell death in cells initially resistant
to ABT-737/etoposide-induced cell death (such as
PCTC#LGG-2) would suggest that among the potential
pre-tropic effects of folate, some of them have the capacity
to restore the caspase activation because ABT-737-induced
apoptosis is caspase-dependent (van Delft et al. 2006).
Besides, this point is consistent with what we have recently
reported and the fact that folate treatment has the capacity
to methylate the promoter region of survivin gene, i.e., a
gene coding for an anti-apoptotic protein able to block
apoptosis by inhibiting the caspases (Shin et al. 2001;
Hervouet et al. 2009).
By dissecting a mechanism generating the phenotype
of apopto-resistance in a context of malignant transfor-
mation induced by (or associated with) the activation of
PDGF signaling pathway, our data open a new door to a
better management of LGG by proposing new therapies
including folate and ABT-737 as “amplificators” of
response to usual chemotherapeutic drugs, and developed
in association with the detection of biomarkers providing
a better rationalization and personalization of anti-glioma
treatments.
Materials and methods
Analyses of DNA methylation
DNA was extracted by using the QiaAmp DNA mini Kit
(Qiagen, France). Four micrograms of genomic DNA was
treated with the EZ DNA methylation Gold kit (Zymo
Research/Proteigene, France) according to the manufac-
turer’s instructions. Five microliters of bisulfite DNA was
used for methylation-specific PCR analysis.
qPCR
RNA was isolated from cells by using the RNeasy Mini Kit
(Qiagen,France).Reactionswere realized in triplicate byusing
the Multiplex Quantitative PCR system (Mx40000), qPCR
Core Reagent kit (Stratagene). PDGFrβ: TGCCTCAGC
CAAATGTCACCTGC and TCACCACCTCGTATTCC;
PUMA: GAAGAGCAAATGAGCCAAACG and GGAG
CAACCGGCAAACG; Bim: TGGCAAAGCAACCTTCT
GATG and GCAGGCTGCAATTGTCTACCT. Bcl-xl: GATG
GAGGAACCAGGTTGTG and CCCCGGAAGGTCTTTTG
TAT. Relative expression was calculated using the 2
–Ct method.
Western blot and immunoprecipitation
In brief, proteins were size fractionated by sodium dodecyl
sulfate–polyacrylamide gel electrophoresis. Proteins were
transferred onto nitrocellulose or PVDF membrane. Satu-
ration and blotting were realized by using SNAP i.d™
Protein Detection System (Millipore, France). The detection
of proteins was performed using ECL™ (GE-Amersham
Biosciences, France) chemiluminescence reagents. Bands
were quantified using Quantity One® quantification soft-
ware (BioRad, France). Immunoprecipitations were realized
by using the Catch and Release® v2.0 Reversible Immu-
noprecipitation System (Millipore, France). Antibodies
used are listed in Table S1.
Transcriptional activity
We used Fugene6 reagent (Roche, France) to transfect the
cells with 200 ng of each pTransLuc (Ozyme, France), with
10 ng of CMV-Renilla luciferase. Day 0 was obtained 24 h
after transfections. At each time point, cells were harvested,
and protein extracts were prepared for dual luciferase assay
as described by the manufacturer (Promega, France), and
luciferase levels were normalized to Renilla luciferase
activity.
Statistical analysis
According to the internal committee of bioethics, the
overall survival time was measured from the date of
surgical resection to the last follow-up visit or death.
Patients with tumor recurrence were censored. Data in bar
graphs are expressed as the mean ± SD. Each result is
representative of, at least, three independent experiments.
Ntv-a/LacZ and Ntv-a/PDGF cells
These cells come from the laboratory directed by Dr. Eric
C. Holland (Memorial Sloan Kettering Cancer Center, New
York, USA; Dai et al. 2001). Ntv-a cells were cultivated
with Dulbecco's modified Eagle's medium (DMEM) with
10% fetal bovine serum and antibiotics. Folate treatment
was performed by adding 4 μg/ml of folic acid into the
DMEM medium. Thus, the concentration of folic acid was
multiplied by two when cells were treated with folate
treatment since DMEM contains 4 μg/ml of folic acid
according to the manufacturer’s information.
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